Entrega mediada por electroporación de ribonucleoproteínas Cas9 y ARNm en hepatocitos primarios de ratón recién aislados

Overview

This protocol outlines a straightforward and reproducible method for isolating primary mouse hepatocytes and utilizing CRISPR-Cas9 for gene editing. The approach facilitates the generation of in vitro and in vivo disease models by disrupting target genes associated with liver metabolic diseases.

Key Study Components

Area of Science

• Gene editing
• Hepatocyte isolation
• Metabolic disease modeling

Background

• Primary mouse hepatocytes are crucial for studying liver functions and diseases.
• CRISPR-Cas9 technology allows for precise gene modifications.
• Isolated hepatocytes can be used for therapeutic applications.
• Challenges exist in the technical aspects of the isolation and editing processes.

Purpose of Study

• To provide a reliable method for gene editing in primary mouse hepatocytes.
• To enable the creation of disease models for inherited metabolic disorders.
• To facilitate potential therapeutic strategies through cell transplantation.

Methods Used

• Isolation of primary mouse hepatocytes from the liver.
• Electroporation of CRISPR-Cas9 ribonucleoproteins and mRNA.
• Assessment of cell viability and gene modification efficiency.
• Demonstration of techniques by experienced researchers.

Main Results

• High viability of isolated hepatocytes post-electroporation.
• Significant levels of gene modification achieved.
• Successful demonstration of the procedure by trained personnel.
• Potential for future applications in patient-specific therapies.

Conclusions

• The described techniques are effective for gene editing in hepatocytes.
• They hold promise for advancing research in metabolic liver diseases.
• Careful adherence to protocols is essential for success.

Frequently Asked Questions